Development and clinical application of recombinant polyclonal antibodies
Monoclonal antibodies (mAbs) have transformed the treatment of cancer and immune disorders, but their single-target nature limits efficacy against heterogeneous tumors and mutating pathogens. Recombinant polyclonal antibodies (RPABs)—defined as mixtures of typically 2–25 defined mAbs produced as a single drug substance...